RecruitingNCT06950814

Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study

Sponsor

West China Hospital

Enrollment

50 participants

Start Date

Apr 5, 2025

Study Type

OBSERVATIONAL

Conditions

Liver Cancer Adjuvant Therapy Sarcomatoid Carcinoma

Summary

In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is a retrospective review (looking back at medical records) examining patients who had surgery for primary hepatic sarcomatoid carcinoma — a rare and aggressive type of liver cancer — to understand whether additional treatments after surgery (adjuvant therapy) improve survival outcomes. **You may be eligible if...** - You have undergone liver surgery (resection) - Your post-surgery pathology results confirm a diagnosis of primary hepatic sarcomatoid carcinoma **You may NOT be eligible if...** - You received other cancer treatments before surgery (such as ablation, chemoembolization, radiation, or systemic therapy) - You were diagnosed with a different specific sarcoma type - You had another cancer at the same time - Your medical records are incomplete or you were lost to follow-up Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREpostoperative adjuvant therapy

Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.

Locations(1)

West China Hospital

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06950814

Related Trials

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

NCT067531361 location

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

NCT004510221 location